Trial Profile
A phase II, randomized, double-blind, dose-titration study investigating the safety and tolerability of retigabine (ezogabine) in partial-onset seizure patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2015
Price :
$35
*
At a glance
- Drugs Retigabine (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors Wyeth Pharmaceuticals
- 29 Sep 2015 New trial record